Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Less weight gain with new diabetes drug

  • 1 Comment

A new drug offers significant advantages over existing treatments for type 2 diabetes patients who do not respond to metformin, suggest findings from a trial in the Lancet online.

Treatment with Linagliptin (Tradjenta) resulted in significantly less weight gain than a commonly-used second-line treatment, the sulphonylurea glimepiride, and may carry a smaller risk of cardiovascular events, according to researchers from Tübingen University Hospital in Germany and the drug’s manufacturer Boehringer Ingelheim.

The two-year trial compared linagliptin with glimepiride in more than 1,500 diabetes patients from 16 countries. 

Lead author Professor Baptist Gallwitz said: “Since hypoglycaemia can have substantial negative clinical consequences in terms of cognitive function, mortality, morbidity, adherence to treatment, and quality of life, its prevention is a crucial component of any diabetes management programme.”

The trial results are published online in the Lancet.

  • 1 Comment

Readers' comments (1)

  • It is well known that sullphoylureas cause weight gain and gliptins don't isn't it?

    Unsuitable or offensive? Report this comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs